Cypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systemsproducts and services

Cypex - in vitro drug metabolism systemsabout us

Cypex - in vitro drug metabolism systemslatest news

Cypex - in vitro drug metabolism systemsdata sheets
Cypex - in vitro drug metabolism systemspublications
Cypex - in vitro drug metabolism systemsfrequently asked questions
Cypex - in vitro drug metabolism systemsassays
Cypex - in vitro drug metabolism systemscontact us
linksCypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systems
bio-dundee logoscottish enterprise biotech
products and services
 

Cypex CYP4F2 QC Assays

Activity: Leukotriene B4 omega-hydroxylase

Incubation conditions
Assay buffer: 0.1 M potassium phosphate pH 7.4, 5 mM MgCl2
Incubation volume: 50 µl
Stop reagent: acetonitrile/acetic acid, 98/2 (v/v) (25 µl)
Internal standard: not used

HPLC conditions
Column: HyperClone ODS (5 µm) 250 x 4 mm
Temperature: 30°C
Mobile phase: 100 mM ammonium acetate (pH 5.6)/water/methanol 20/35/45 (% v/v/v) initially (gradient separation)
Flow rate: 1.0 ml/min
Run time: 15.5 min
Injection volume: 50 µl
Detection: UV (DAD),
l = 271 nm
Retention times:
      omega-
hydroxy-LTB4      10.0 min
      Leukotriene B4               13.2 min

 

Effect of phosphate concentration on leukotriene B4 turnover by CYP4F2BLR Bactosomes
Leukotriene B4 turnover by CYP4F2 is very sensitive to the concentration of phosphate in the incubation.

This assay was carried out at 100 µM leukotriene B4 at a P450 concentration of 2.5 pmol per 50 µl.

 

 

Made under licence from BTG International Ltd (AU730155, EP0914446, US6566108 and other patents pending).

United States Patent Nos. 5,420,027 or 5,240,831, Canada Patent No. 2100245 and other patents pending.

PRODUCTS & SERVICES | ABOUT US | LATEST NEWS | DATA SHEETS | PUBLICATIONS | FAQ'S | ASSAYS | CONTACT US | LINKS | INTRO | TERMS | HOME
Designed and created by Rob Cook at Limehouse Design